Dowpharma Signs Agreement with Japanese Distributor to Market Pharmaceutical Services in Japan

Midland, MI - March 14, 2003

Dowpharma^SM, a business unit of The Dow Chemical Company signed an agreement with CBC Co. Ltd (Tokyo, Japan) to be its representative in marketing its pharmaceutical services to Japanese drug makers. The agreement was developed out of an existing relationship that CBC had with Chirotech, which was part of the Ascot acquisition that Dow made in 2001. Chirotech, a global leader in chiral technology, is part of the Dowpharma business.

"CBC Co. Ltd. has considerable expertise in pharmaceutical products and services while understanding our offering, so they will be able to communicate our capabilities to perspective customers", states Gwin Bompas, Dowpharma commercial director for Europe and Asia/Japan. CBC will also assist Dowpharma in obtaining technology licenses from identified Japanese authorities and companies. Due to the language, cultural and time zone differences, CBC will interface as Dowpharma's local agent to help Dowpharma grow its business in the Japanese pharmaceutical market.

As the Japanese government recently made it legal for pharmaceutical companies to outsource the manufacture of active pharmaceutical ingredients Dowpharma believes it's positioned very favorably with its extensive offering. Dowpharma has a large toolbox of enabling technologies, including a wide selection of industrially ready chiral technologies, along with a stellar regulatory record that will benefit pharmaceutical companies to bring their drugs to market quicker and more efficiently. "We see growth opportunities, as Japan is one of the largest pharmaceutical markets and will need contract manufacturing organizations that can support a wide range of offerings/services along with customized solutions, and Dowpharma has the breadth and depth to meet a variety of needs," states Bompas.

CBC and Dowpharma will be exhibiting at the upcoming event, CPhI Japan which will be held April 15-17 in Tokyo.

About Dowpharma
As part of Dow’s Custom & Fine Chemicals global business unit, Dowpharma serves the pharmaceutical and biopharmaceutical industries with innovative technology, products and services for clients in drug discovery, development, manufacturing and delivery. Dowpharma combines the resources and capabilities of several entities to create a single, market focused organization with broad service and support capabilities for large and emerging pharmaceutical companies.

Dowpharma services include process development, route selection, methods development and associated analytical services and manufacturing and scale-up from the bench through clinical trials and to commercial launch. Dowpharma currently manufactures small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, oligonucleotides, peptides, cGMP polymers and proteins from microbial fermentation.

Dowpharma has a 20-plus year history of pristine cGMP regulatory compliance in the organic synthesis of APIs and pharmaceutical intermediates with the ability to provide client support in filing and validation strategies. The business also manufactures a long list of scaffolds and fine chemicals of interest to the drug development community. This business combines personnel and assets from Dow’s Contract Manufacturing Services business with those from Chirotech Technology Limited, Mitchell Cotts Chemicals, Hampshire Chemical Corp., and Dow Biopharmaceutical Contract Manufacturing Services. Dowpharma operates research, process development and manufacturing facilities in North America and Europe.

For more information on Dowpharma, visit: www.dowpharma.com.

About Dow
Dow is a leading science and technology company that provides innovative chemical, plastic and agricultural products and services to many essential consumer markets. With annual sales of $27 billion, Dow serves customers in more than 170 countries and a wide range of markets that are vital to human progress, including food, transportation, health and medicine, personal and home care, and building and construction, among others. Committed to the principles of Sustainable Development, Dow and its approximately 50,000 employees seek to balance economic, environmental and social responsibilities.

For Editorial Information:

Kathleen Wilson
The Dow Chemical Company
989-636-2760


Capabilities and Services Biocatalysis Biocatalysis Capability Collaborators Enzyme Classes Chemocatalysis Asymmetric Hydrogenation Hydroformylation Trost Allylic Alkylation Complex Synthesis Products Offered Process Development Customer Needs Development Timeline Emerging Pharma Catalyst/Ligand Availability Unnatural Fmoc Amino Acids Unnatural Boc Amino Acids 2-Alkyl Succinates Amines Alcohols Functionalized Cyclopentanes Scaffolds Facilities Literature and Resources Asymmetric Hydrogenation Dowpharma Scientific Publications Hydroformylation Trost Allylic Alkylation Complex Synthesis Biocatalysis Process Development General Publications News Source: Aquapharm Bio-Discovery Ltd Enters a Collaboration Deal with Dowpharma<sup>SM</sup> Contract Manufacturing Services. Dowpharma Relaunches Web Site, Will Make Donation to UNICEF Dow Expands Presence in Pharmaceutical Market, Uniting Existing Offers Under Dowpharma Portfolio Dowpharma Announces New Capabilities in Asymmetric Hydroformylation for Pharmaceutical Applications License of JST Catalyst Technology Expands Dowpharma’s Chiral Commercial Production Capabilities Dowpharma Signs Agreement with Japanese Distributor to Market Pharmaceutical Services in Japan Events Calendar REACH Contact Us	Dowpharma Signs Agreement with Japanese Distributor to Market Pharmaceutical Services in Japan Midland, MI - March 14, 2003 Dowpharma^SM, a business unit of The Dow Chemical Company signed an agreement with CBC Co. Ltd (Tokyo, Japan) to be its representative in marketing its pharmaceutical services to Japanese drug makers. The agreement was developed out of an existing relationship that CBC had with Chirotech, which was part of the Ascot acquisition that Dow made in 2001. Chirotech, a global leader in chiral technology, is part of the Dowpharma business. "CBC Co. Ltd. has considerable expertise in pharmaceutical products and services while understanding our offering, so they will be able to communicate our capabilities to perspective customers", states Gwin Bompas, Dowpharma commercial director for Europe and Asia/Japan. CBC will also assist Dowpharma in obtaining technology licenses from identified Japanese authorities and companies. Due to the language, cultural and time zone differences, CBC will interface as Dowpharma's local agent to help Dowpharma grow its business in the Japanese pharmaceutical market. As the Japanese government recently made it legal for pharmaceutical companies to outsource the manufacture of active pharmaceutical ingredients Dowpharma believes it's positioned very favorably with its extensive offering. Dowpharma has a large toolbox of enabling technologies, including a wide selection of industrially ready chiral technologies, along with a stellar regulatory record that will benefit pharmaceutical companies to bring their drugs to market quicker and more efficiently. "We see growth opportunities, as Japan is one of the largest pharmaceutical markets and will need contract manufacturing organizations that can support a wide range of offerings/services along with customized solutions, and Dowpharma has the breadth and depth to meet a variety of needs," states Bompas. CBC and Dowpharma will be exhibiting at the upcoming event, CPhI Japan which will be held April 15-17 in Tokyo. About Dowpharma As part of Dow’s Custom & Fine Chemicals global business unit, Dowpharma serves the pharmaceutical and biopharmaceutical industries with innovative technology, products and services for clients in drug discovery, development, manufacturing and delivery. Dowpharma combines the resources and capabilities of several entities to create a single, market focused organization with broad service and support capabilities for large and emerging pharmaceutical companies. Dowpharma services include process development, route selection, methods development and associated analytical services and manufacturing and scale-up from the bench through clinical trials and to commercial launch. Dowpharma currently manufactures small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, oligonucleotides, peptides, cGMP polymers and proteins from microbial fermentation. Dowpharma has a 20-plus year history of pristine cGMP regulatory compliance in the organic synthesis of APIs and pharmaceutical intermediates with the ability to provide client support in filing and validation strategies. The business also manufactures a long list of scaffolds and fine chemicals of interest to the drug development community. This business combines personnel and assets from Dow’s Contract Manufacturing Services business with those from Chirotech Technology Limited, Mitchell Cotts Chemicals, Hampshire Chemical Corp., and Dow Biopharmaceutical Contract Manufacturing Services. Dowpharma operates research, process development and manufacturing facilities in North America and Europe. For more information on Dowpharma, visit: www.dowpharma.com. About Dow Dow is a leading science and technology company that provides innovative chemical, plastic and agricultural products and services to many essential consumer markets. With annual sales of $27 billion, Dow serves customers in more than 170 countries and a wide range of markets that are vital to human progress, including food, transportation, health and medicine, personal and home care, and building and construction, among others. Committed to the principles of Sustainable Development, Dow and its approximately 50,000 employees seek to balance economic, environmental and social responsibilities. For Editorial Information: Kathleen Wilson The Dow Chemical Company 989-636-2760
	Small Molecules Dow Home Privacy Statement Internet Disclaimer Accessibility Statement Site Map Copyright © The Dow Chemical Company (1995-2008). All Rights Reserved.